Cabozantinib in Advanced Salivary Gland Cancer Patients

Sponsor
Radboud University Medical Center
Study ID
NCT03729297
Phase
PHASE2
Status
Terminated

Conditions

  • Salivary Gland Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.

Study Details

Phase 2 clinical trial on the efficacy of cabozantinib in locally advanced, recurrent and/or metastatic salivary gland cancer patients.

Key Dates

Start date
Sep 5, 2018
Status verified
Nov 2019
Primary completion
Nov 6, 2019
Completion
Nov 6, 2019

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: cabozantinib
    cabozantinib 60 mg tablets OD

Primary Outcome Measure

overall response rate [ Time Frame: every 8 weeks (first year of treatment) and every 12 weeks (second year of treatment) a CT/MRI scan will be made to asses the response rate until progressive disease ]

Related Studies